The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Precemtabart tocentecan (Precem-TcT, M9140) in patients with mCRC: Efficacy and safety data at the recommended development dose in the PROCEADE-CRC-01 study.
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Lutris; Navire
Consulting or Advisory Role - Alentis Therapeutics; AmMax Bio; Arcus Biosciences; AstraZeneca; AVEO; BeiGene; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Carina Biotech; Clasp Therapeutics; Cytovation; Dewpoint Therapeutics; EMD Serono; Erasca, Inc; Flame Biosciences; Frontier Medicines; Genentech; Harbinger Oncology, Inc; Ikena Oncology; Iterion Therapeutics; Kivu Biosciences; Marengo Therapeutics; Pfizer; Regeneron; Roche; SageMedic; SERVIER; Shionogi; T-Cypher Bio; Tachyon Therapeutics; Transcode; XAIRA Therapeutics; Zentalis; Zentalis
Research Funding - Boehringer Ingelheim; EMD Serono; Genentech; Pfizer; Roche; Zentalis
 
Rocio Garcia-Carbonero
Honoraria - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZeneca (I); Bayer; BMS; Boehringer Ingelheim; Crinetics Pharmaceuticals; Esteve; Gilead Sciences (I); GlaxoSmithKline; Hutchmed; Ipsen; Isotopen Technologien; Lilly (I); Merck; Mirati Therapeutics (I); MSD; Novocure; Pfizer (I); PharmaMar; Roche (I); Sanofi; Servier; Takeda
Research Funding - BMS (Inst); MSD (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Advanced Accelerator Applications/Novartis; Esteve; Ipsen; Merck; MSD
 
Sae-Won Han
Consulting or Advisory Role - Abbvie; AstraZeneca; Natera
Research Funding - Abbvie (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeyondBio (Inst); Boryung (Inst); Cell Biotech (Inst); GC Pharma (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); Hengrui Pharmaceutical (Inst); IMBdx (Inst); Janssen (Inst); Jeil Pharmaceutical Co (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck KGaA (Inst); Mirati Therapeutics (Inst); MSD (Inst); Roche (Inst); Seagen (Inst)
 
Ildefonso Rodriguez-Rivera
Employment - Next Oncology; Texas Oncology
Stock and Other Ownership Interests - Next Oncology; Texas Oncology
Consulting or Advisory Role - Cardinal Health; Syneos Health; Telix Pharmaceuticals; Werewolf Therapeutics
 
Jose Ruffinelli
Travel, Accommodations, Expenses - Advanced Accelerator Applications/Imaging Equipment Ltd; Amgen Astellas BioPharma; EMD Serono/Merck; MSD
 
Valentina Boni
Employment - Next Oncology; Next Oncology; Quironsalud
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - 1TRIALSP
Honoraria - Amunix; EMD Serono/Merck; Guidepoint Global; IDEAYA Biosciences; Janssen Oncology; Loxo; MSD Oncology; Puma Biotechnology
Consulting or Advisory Role - EMD Serono/Merck; Guidepoint Global; Janssen Research & Development; Lilly; Lilly; Nanobiotix; Novartis; OncoArt
Speakers' Bureau - Lilly; MSD; Solti; TACTICS; TACTICS
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Genmab (Inst); Incyte (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Menarini (Inst); Merck (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Synthon (Inst); Tesaro (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Bayer; START
 
Maria Vieito
Consulting or Advisory Role - BMS; myTomorrows; SERVIER
Speakers' Bureau - Novocure
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Novartis (Inst); Roche; Roche/Genentech (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst)
Travel, Accommodations, Expenses - Roche
Other Relationship - BMS GmbH & Co. KG (Inst); Debiopharm Group (Inst); HUTCHMED (Inst); Incyte (Inst); Mundipharma (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst); SERVIER (Inst); Taiho Oncology (Inst)
 
Maria J. de Miguel
Honoraria - HiFiBiO Therapeutics; MSD Oncology; PharmaMar
Travel, Accommodations, Expenses - Lilly
(OPTIONAL) Uncompensated Relationships - Abbvie; Abbvie; Array BioPharma; Genmab; HiFiBiO Therapeutics; Janssen; Lilly; MSD; Novartis; PharmaMar; Roche; Salubris Biotherapeutics; Sanofi; Seagen; SERVIER
 
Simona Blotta
Employment - EMD Serono/Merck
Stock and Other Ownership Interests - Merck KGaA
 
Christina Habermehl
Employment - EMD Serono
 
Abdul Siddiqui
Employment - Merck Serono
 
Nancy Schoenherr
Employment - Merck KGaA
 
Jatinder Kaur Mukker
Employment - EMD Serono
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca; BeiGene; Chugai Pharma; Daiichi Sankyo/UCB Japan; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Beigene (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)